| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy. Patients with MB leprosy received ROM (n = 10) or World Health Organization multi-drug therapy (MDT) (n = 11). Treatment with ROM was given as 24 consecutive monthly observed doses of rifampin (600 mg), ofloxacin (400 mg), and minocycline (100 mg). Treatment with MDT was given as 24 consecutive monthly observed doses of rifampin (600 mg) and clofazimine (300 mg), and unobserved daily dapsone (100 mg) and clofazimine (50 mg). Twenty patients completed the 24-month regimens with > 99% compliance. Treatments with ROM and MDT were safe, tolerable, and caused similar improvements in lesions, bacterial indices, and histology. All MDT recipients developed clofazimine-induced pigmentation. Six ROM and nine MDT recipients assessed at five or more years after completion of treatment had no evidence of relapse. Twenty-four months of treatment with ROM is a safe, well-tolerated, and convenient regimen that may provide an alternate therapy to MDT for MB leprosy. Larger trials with sufficient follow-up would better define the role of ROM.
Received July 7, 2003. Accepted for publication September 25, 2003.
Acknowledgments: We thank the Sasakawa Memorial Health Foundation (Tokyo, Japan) for supplying World Health Organization-multi-drug therapy drugs and United Laboratories for supplying ofloxacin. We also thank Paulina Munalem, Amparo Pepito, Loida Gabiana, Guillerma Lim, and Pris Reed for support. This work was presented in part at the 15th Annual International Leprosy Congress, 1998, Beijing, People’s Republic of China.
Disclaimer: The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official or as reflecting the views of the U.S. Department of the Army or the Department of Defense.
Authors’ addresses: Laarni G. Villahermosa, Tranquilino T. Fajardo, Jr., Rodolfo M. Abalos, Roland V. Cellona, Maria V. Balagon, Eduardo C. Dela Cruz, and Esterlina V. Tan, Leonard Wood Memorial Center for Leprosy Research, PO Box 727, Cebu City 6000, The Philippines. Douglas S. Walsh, Dermatology Service, Eisenhower Army Medical Center, Fort Gordon, GA 30905.
Reprint requests: Douglas S. Walsh, Dermatology Service, Eisenhower Army Medical Center, Fort Gordon, GA 30905, Telephone: 706-787-1472, Fax: 706-787-1354, E-mail: douglas.walsh{at}se.amedd.army.mil.
This article has been cited by other articles:
|
|
 |
|
  A. Cusini, H. F Gunthard, R. Weber, M. Huber, J. Kamarashev, B. Bertisch, S. Peter, and B. Beck Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1 infected patient after initiation of antiretroviral therapy BMJ Case Reports, December 1, 2009; 2009(dec01_1): bcr0520091904 - bcr0520091904. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. F. Balagon, R. V. Cellona, E. d. Cruz, J. A. Burgos, R. M. Abalos, G. P. Walsh, P. R. Saunderson, and D. S. Walsh Long-Term Relapse Risk of Multibacillary Leprosy after Completion of 2 Years of Multiple Drug Therapy (WHO-MDT) in Cebu, Philippines Am J Trop Med Hyg, November 1, 2009; 81(5): 895 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Marcus, B. H. Mahmoud, and I. H. Hamzavi Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy Arch Dermatol, July 1, 2009; 145(7): 787 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. G. VILLAHERMOSA, T. T. FAJARDO JR, R. M. ABALOS, M. V. BALAGON, E. V. TAN, R. V. CELLONA, J. P. PALMER, J. WITTES, S. D. THOMAS, K. A. KOOK, et al. A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, CONTROLLED DOSE COMPARISON OF THALIDOMIDE FOR TREATMENT OF ERYTHEMA NODOSUM LEPROSUM Am J Trop Med Hyg, May 1, 2005; 72(5): 518 - 526. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
